Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication

Simply Wall St.03-23

Rhythm Pharmaceuticals (RYTM) is back in focus after the FDA approved a broader label for IMCIVREE to treat acquired hypothalamic obesity in patients aged 4 and up, supported by Phase 3 TRANSCEND data...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621720467?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-23 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621720467","market":"us","top_or_hot":-1,"title":"Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication","media":"Simply Wall St.","content":"<div>\n<p>Rhythm Pharmaceuticals (RYTM) is back in focus after the FDA approved a broader label for IMCIVREE to treat acquired hypothalamic obesity in patients aged 4 and up, supported by Phase 3 TRANSCEND data...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/assessing-rhythm-pharmaceuticals-rytm-valuation-after-fda-ap\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/assessing-rhythm-pharmaceuticals-rytm-valuation-after-fda-ap><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rhythm Pharmaceuticals (RYTM) is back in focus after the FDA approved a broader label for IMCIVREE to treat acquired hypothalamic obesity in patients aged 4 and up, supported by Phase 3 TRANSCEND data...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/assessing-rhythm-pharmaceuticals-rytm-valuation-after-fda-ap\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/assessing-rhythm-pharmaceuticals-rytm-valuation-after-fda-ap","article_id":"2621720467","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/assessing-rhythm-pharmaceuticals-rytm-valuation-after-fda-ap","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621720467","pubTimestamp":1774260429,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Rhythm Pharmaceuticals (RYTM) is back in focus after the FDA approved a broader label for IMCIVREE to treat acquired hypothalamic obesity in patients aged 4 and up, supported by Phase 3 TRANSCEND data.\nSee our latest analysis for Rhythm Pharmaceuticals.\nDespite the FDA approval and new PANTHERx distribution agreement, Rhythm Pharmaceuticals’ recent share price performance has softened. The 30 day share price return shows a decline of 12.36% and the 90 day share price return shows a decline of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc.","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","USD":"ProShares Ultra Semiconductors","BK4585":"ETF&股票定投概念","BK4139":"生物科技","USD.AU":"BETASHARES US DOLLAR ETF"},"translate_title":"FDA批准扩大IMCIVREE的肥胖适应症后评估Rhythm Pharmaceuticals(RYTM)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"USD.AU":1,"RYTM":1.5,"USD":1},"content_text":"Rhythm Pharmaceuticals (RYTM) is back in focus after the FDA approved a broader label for IMCIVREE to treat acquired hypothalamic obesity in patients aged 4 and up, supported by Phase 3 TRANSCEND data. See our latest analysis for Rhythm Pharmaceuticals. Despite the FDA approval and new PANTHERx distribution agreement, Rhythm Pharmaceuticals’ recent share price performance has softened. The 30 day share price return shows a decline of 12.36% and the 90 day share price return shows a decline of 22.16%, while the 1 year total shareholder return is 62.79% and the 3 year total shareholder return is a little over 4x, pointing to strong long term gains alongside fading short term momentum. If this kind of rare disease catalyst interests you, it can be useful to see what else is moving in adjacent areas using our healthcare focused screeners such as 36 healthcare AI stocks With Rhythm now valued at about US$6.0b, trading at US$87.45 and sitting roughly 44% below the average analyst price target, the key question is whether this rare disease story is still mispriced or if the market is already looking ahead and factoring in future growth. AdvertisementMost Popular Narrative: 33.5% Undervalued According to Vestra's narrative, Rhythm Pharmaceuticals' fair value of $131.50 sits well above the recent close at $87.45, framing a sizeable valuation gap for investors to weigh.  The fair value for Rhythm Pharmaceuticals (RYTM) is calculated using my fair value method by projecting Unlevered Free Cash Flow through 2030 and discounting it using a 14.1% WACC to account for the \"Biotech Risk Premium\" and current operational burn. This results in a fair value of $131.50 in local currency (USD). At the current price of $93.52, the stock is trading at a 28.9% discount to its intrinsic value. I arrived at this fair value by assigning a 90% probability of HO approval following the stellar TRANSCEND data; this calculation affects the stock by identifying it as an undervalued \"Strong Buy\" ahead of the March 20th catalyst, as the market has not yet fully priced in the projected $3.0 billion in peak revenue by 2030.  Read the complete narrative. Curious what sits behind that fair value, beyond the headline price gap? The narrative leans heavily on revenue compounding, margin uplift, and a specific path to future profitability. The full story breaks down how those inputs tie back to one MC4R focused commercial model and a single high impact regulatory decision. Result: Fair Value of $131.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on IMCIVREE execution and MC4R pipeline progress, so any clinical, regulatory, or reimbursement setbacks could quickly challenge that underpricing story. Find out about the key risks to this Rhythm Pharmaceuticals narrative. Another View: Rich Price Tag on Sales That 33.5% undervalued fair value contrasts with a much tougher message from Rhythm’s current P/S of 31.5x. The fair ratio sits at 20.3x, while peers sit near 6.8x and the wider US Biotechs industry around 10.7x. This means investors are already paying up heavily for the story, so how comfortable are you with that premium valuation risk? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:RYTM P/S Ratio as at Mar 2026Next Steps With sentiment split between valuation risk and long term opportunity, it helps to see the full picture for yourself and move quickly while views are still forming. You can start with the 3 key rewards. Looking for more investment ideas? If you stop with just one stock, you risk missing other opportunities that might fit your style even better. Keep broadening your watchlist with focused tools.  Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations using the 54 high quality undervalued stocks. Build a stronger income base by reviewing companies offering higher yields and resilient payouts via the 13 dividend fortresses. Sleep easier at night by checking out companies that score well on stability and financial risk using the 72 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621720467","isCrawlerRequest":true}